Critical Comparison: Shattuck Labs (NASDAQ:STTK) and Cullinan Therapeutics (NASDAQ:CGEM)

Shattuck Labs (NASDAQ:STTK) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Shattuck Labs and Cullinan Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1	0	9	2	3.00
Cullinan Therapeutics	1	1	6	1	2.78

Shattuck Labs currently has a consensus price target of $12.78, indicating a potential upside of 84.92%. Cullinan Therapeutics has a consensus price target of $32.86, indicating a potential upside of 49.76%. Given Shattuck Labs’ stronger consensus rating and higher probable upside, equities analysts clearly believe Shattuck Labs is more favorable than Cullinan Therapeutics.

Risk and Volatility

Shattuck Labs has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500.

Profitability

This table compares Shattuck Labs and Cullinan Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

Institutional & Insider Ownership

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Shattuck Labs and Cullinan Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1.00 million	693.49	-$48.81 million	($0.51)	-13.55
Cullinan Therapeutics	N/A	N/A	-$219.88 million	($3.10)	-7.08

Shattuck Labs has higher revenue and earnings than Cullinan Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Shattuck Labs beats Cullinan Therapeutics on 11 of the 13 factors compared between the two stocks.

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.